Genmab Takes On Big Commercial Challenge With Merus Buyout

 
• By Andrew McConaghie
  
Jan van de Winkel
CEO Jan van de Winkel is overseeing Genmab's transition away from reliance on royalty revenue - but this brings new clinical and commercial challenges. • Source: Genmab
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D